4SC Discovery and CRELUX enter into strategic alliance
The biotech company 4SC AG announced that its drug discovery affiliate 4SC Discovery GmbH and CRELUX GmbH have entered into a strategic partnership for integrated drug discovery services. Both partners are adding core competencies to a joint discovery platform geared towards comprehensive drug discovery services under one roof. Pharma and Biotech customers will get quick and affordable high quality services for the discovery and optimization of novel small molecule drugs.
The integrated drug discovery platform i2c (idea to candidate) offers a seamless process from early concept through to a preclinical development candidate ready to advance into formal animal model testing and thereafter into clinical trials. The i2c client groups are pharma companies looking to outsource part of their early discovery projects and also small and mid-size biotech companies lacking the relevant infrastructure. Besides the standard fee-for service offerings i2c also includes research collaborations based on risk sharing models including milestones and royalties. These collaborations are provided as tailor made solutions for smaller sized companies and interested pharma partners.
Other news from the department business & finance
